> Teva and Barr Pharmaceuticals both got FDA approval for their generic versions of Merck's osteoporosis drug Fosamax, which went off patent yesterday. Report [1]
> India's Ranbaxy got the tentative FDA nod for its copycat form of AstraZeneca's Nexium heartburn pill, which is still under patent. Report [2]
> Millennium Pharmaceuticals posted fourth-quarter profits of $41.06 million on revenues of $181.19 million. Report [3]
> Wyeth hired Timothy Cost to be senior vice president for corporate affairs; previously, cost handled corporate affairs at ARAMARK. Report [4]
> Swiss-based Octapharma is moving its U.S. headquarters to a 15,000-square-foot facility in Hoboken, NJ. Report [5]
> Biogen Idec reported a big boost in quarterly profits, largely due to strong sales of its multiple sclerosis drugs and a cancer med it markets jointly with Genentech. Report [6]
> French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's potential side effects. Report [7]
> A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. Report [8]
> Speculation over the prospective acquisition of CeNeS continued to mount as the company's shares shot up 70 percent yesterday. Report [10]
> AstraZeneca is shaking up its global R&D efforts [11], planning to slash some 300 research positions at a major complex in the U.K. Report [12]
> The most efficient drug development programs will rely on contributions from a variety of companies, with partnerships and outsourcing providing unique expertise to advance new therapies, according to a new study from Tufts Center for the Study of Drug Development. Report [9]
And Finally... Prescription mac-and-cheese? Kraft Foods is working on products that will contain plant oils to kill intestinal parasites such as tapeworms. Report [13]
Links:
[1] http://orange.advfn.com/news_Teva-Barr-get-FDA-OK-for-generic-drug_24600058.html
[2] http://www.forbes.com/markets/2008/02/07/ranbaxy-nexium-approval-markets-equity-cx_rd_0207markets03.html
[3] http://www.rttnews.com/sp/Quickfactsnew.asp?item=62
[4] http://www.agrimarketing.com/show_story.php?id=48039
[5] http://hoboken411.com/archives/10478
[6] http://www.marketwatch.com/news/story/biogen-idec-shares-gain-profit/story.aspx?guid=%7BC5E12AB8-A3AE-4B7D-8796-3812C354DC00%7D
[7] http://www.fiercebioresearcher.com/vaccines/story/france-probe-gsk-sanofi-vaccination-campaign/2008-02-07
[8] http://www.fiercebioresearcher.com/vaccines/story/chimp-virus-plays-key-role-malaria-vaccine/2008-02-07
[9] http://www.fiercebiotech.com/story/efficient-drug-programs-demand-partners-outsourcing/2008-02-06
[10] http://www.fiercebiotech.com/story/speculation-mounts-over-prospective-cenes-buyer/2008-02-06
[11] http://www.fiercebiotech.com/special-reports/2-astrazeneca?utm_medium=nl&utm_source=internal
[12] http://www.fiercebiotech.com/story/astrazeneca-drops-axe-global-r-d-shakeup/2008-02-06
[13] http://www.nytimes.com/2008/02/05/health/research/05kraf.html?ref=health